Good MorningThe S&P 500 closed the day on Friday with a gain of 0.30% to end at another all-time closing high. The move was driven by a rise in optimism despite the rising number of COVID-19 cases but may be short-lived. While the index moved up to set a new closing high there is still resistance at the all-time intraday high. Until the market moves above that level bullish traders should be cautious.
Next week will bring another round of important economic data that could move the market. Topping the list is the monthly Non-Farm Payroll report and unemployment figures. The risk for the market is that an unexpected uptick in jobless claims in November may point to weaker than expected NFP numbers. Until then there is a raft of other data including the Fed’s Beige Book for investors to consider.
Featured: AI CRASH WARNING (Ad) 
|
Consumer Staples | |
The Dow hit 30,000 for the first time yesterday and the S&P 500 surged more than 1.6%. But this wasn’t a day where there was green across the board.
Many of yesterday’s winners were companies that have struggled during the pandemic, but expect to turn it around once a vaccine beco... Read the Full Story |
|
From Our Partners | | Three Nobel Prize Winners expose this once-in-a-generation wealth shift:
“Don’t Say I Didn’t Warn You”
Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change. | | Don’t be left behind. Click here now. |
|
Retail/Wholesale | |
For a while now Best Buy (NYSE: BBY), the $30 billion electronics retailer, has been pinned as one of the better-performing retailers in 2020, a year that has forced many to adapt or die. Coming into yesterday’s release, shares were not only up more than 150% since March, but trading at all-... Read the Full Story |
|
Retail/Wholesale | |
There are different approaches to growing a portfolio. Some investors like to focus on high-flying technology stocks to generate capital appreciation. Others prefer to get their growth in a steadier fashion by investing in companies that have a history of increasing their dividend payments.
Here ... Read the Full Story |
|
From Our Partners | | In 1976, Chevron, Unocal, and Texaco each confirmed the same energy technology worked - no fuel costs, no carbon, no supply chain. All three killed their projects because it threatened their core business.
Now one company has spent sixty years developing what Big Oil refused to touch. Google just signed a 15-year contract, Bill Gates wrote a $100 million check, and on July 4th the government hands it a competitive edge no other energy source receives. | | See the company that spent 60 years perfecting what Big Oil buried |
|
Technology | | Social media platform Pinterest, Inc. (NYSE: PINS) stock has surprised the markets blowing away analyst expectations even after the heads up from Snapchat (NASDAQ: SNAP) earnings. The platform grew its global users to over 442 million. The visual discovery platform where people post up inspirational... Read the Full Story |
|
Markets | | Anaplan, Inc; A Small-Cap Tech Growth Story
Anaplan, Inc (NYSE:PLAN) is emerging as a small-cap growth story for 2021 and beyond. The company operates a cloud-based SaaS platform that connects disparate segments of business for planning purposes. This may not sound like much but when it comes to co... Read the Full Story |
|
From Our Partners | | Analyst Jeff Brown believes biotech could become one of the greatest investment opportunities in a generation, with three converging forces he says could allow investors to double and triple their money repeatedly starting July 23.
Already, select biotech stocks have posted moves of 25%, 108%, 256%, 453%, and 850% in a matter of hours. Brown has developed an AI neural network to help identify the biggest potential moves before they happen. | | Register for Jeff Brown's free biotech briefing on July 1 |
|
Basic Materials | | Diversified energy materials development company Westwater Resources, Inc. (NASDAQ: WWR) stock has recently surged on the electric vehicle (EV) stock mania. Shares are looking to wildly outperform the benchmark S&P 500 index (NYSEARCA: SPY). As money flows into EV related companies ranging from ... Read the Full Story |
|
Consumer Staples | | Dividend King Hormel Raises The Dividend Less Than Expected
Hormel Foods (NYSE:HRL) reported a decent 3rd quarter and yet shares are down more than 5.0% on the news. For those wondering why there are three primary factors in play that will eventually lead to another buying opportunity. The first is... Read the Full Story |
|
Aerospace | |
For decades, General Electric (NYSE:GE) was one of the most respected and renowned industrial companies in the United States. The stock was one of the most reliable performers in the market and consistently rewarded investors with dividend increases over the years. However, the company experienced... Read the Full Story |
|
Retail/Wholesale | | It’s about that time of year when investors start trying to determine which companies will outperform expectations in the year ahead. Get ready to hear the term “pent up demand” in 2021 as much as you’ve heard “new-normal” in 2020.
There are a lot of excellent co... Read the Full Story |
|
Industrials | |
These days, we are seeing more focus than ever before on renewable energy sources that can help to power our daily lives. While most of the headlines have been about electric vehicles and solar power, hydrogen energy is an intriguing alternative power source that has been available for years. The ... Read the Full Story |
|
The Early Bird Stock Of The Day Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. | | View Today's Stock Pick |
|
